Jubilant Pharmova Ltd.

New Delhi: Jubilant Pharmova ended the first quarter of fiscal year 2025-26 with a revenue of ₹1,901 crore, up by 10 per cent from the previous fiscal same quarter. With profit margin recording a sharp increase of 140 basis points, the company’s normalized PAT for the quarter stood at ₹103 crore, reflecting a jump of 48 per cent against the previous fiscal. For the period Reported PAT stood at ₹482 crore, up from ₹396 crore due to one-time net exceptional income. During the April-June quarter Jubilant Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBIDTA) stood at ₹302 crore at an EBIDTA margin of 15.8 per cent. The quarter performance is attributed with the a “strong customer traction in the company’s CDMO Sterile Injectable business” which reported a revenue of ₹370 crore, up by 14 per cent on YoY with a EBITDA of ₹62 crore. Several global drugmakers have placed orders for their generic versions ahead of semaglutide’s patent expiry slated early next year. Jubilant's radiopharmaceutical segment–US specific operations—posted a revenue of ₹271 crore with a marginal increase of 3 per cent on YoY basis while radiopharmacy business clocked ₹598 crore. “The dosing for Phase 2 clinical trial for MIBG is complete and we are preparing data package to be submitted to FDA by H2’FY26 and we are on track to introduce multiple new products in the PET and SPECT imaging from FY27 to FY29,” the company said in a release. Meanwhile, the proposed investment of $50 million (~₹425 crore) in PET radiopharmacy network is underway, it added. According to the company the proposed investment will expound its PET radiopharmacy network to nine sites, and will position it as the second largest radiopharmacy network in the US. Revenue from the generics business stood at ₹172 crore with an EBITDA of ₹12 crore. Sharing an update over its property novel drug pipeline the company said, it is " actively enrolling patients and progressing in line with its expectations.” Jubilant novel pipeline includes JBI -802 for Essential Thrombocythemia (ET), other Myeloproliferative Neoplasms (MPN) and JBI -778, a Phase 1 trail candidate for non-small cell lung cancer (NSCLC) and high grade Glioma. On its future outlook the company stated, “we are ramping up exports to the US markets in a meaningful and gradual manner and plan to launch 6 to 8 products per annum in our US and non-US international markets.” By Online Bureau ,

Seasoned Executives Join to Support AI-Driven Growth in U.S.-Based Biomanufacturing MADISON, Wis., June 16, 2025 /PRNewswire/ -- Axio BioPharma Inc., a next-generation biomanufacturing company using AI to transform mammalian protein production, today announced the continued expansion of its advisory board with the recent addition of Patrick Haffey. He joins existing advisors Dr. Greg Bleck and Dr. Graham Brearley, forming a deeply experienced group of leaders in biologics research, development, and operations. "We're excited to welcome Pat to the advisory board alongside Greg and Graham," said Justin Byers, CEO of Axio BioPharma. "Together, they bring a tremendous depth of expertise in scaling biologics manufacturing and developing strategic partnerships. Their guidance will be invaluable as we expand our AI-enabled platform and grow our operational footprint." Dr. Greg Bleck is a biotech R&D veteran and former Vice President at Catalent Biologics. He has played a key role in the development of more than 175 biologics currently in clinical trials and holds over 20 patents. Dr. Bleck co-founded Gala Design, the precursor to Gala Biotech, and helped pioneer the GPEx® cell line platform, used in the production of numerous approved therapies. Dr. Graham Brearley brings over 30 years of expertise in biologics process development, technology transfer, and global manufacturing operations. He has led large-scale facility expansions and served as site head at multiple biologics manufacturing sites. Throughout his career, he has overseen more than 100 M&A due diligence and integration initiatives and managed over 20 regulatory due diligence reviews and inspections across U.S. and European regulatory agencies. Patrick Haffey, the most recent addition to the board, is a seasoned biopharmaceutical executive with two decades of experience launching and scaling GMP operations around the world. His leadership roles at Samsung Biologics and Jubilant Hollister-Stier include overseeing facility development, quality systems, and regulatory readiness. He has raised over $150 million in capital and established long-term partnerships across the industry. These appointments underscore Axio BioPharma's continued commitment to operational excellence and innovation as it scales its AI-powered biomanufacturing platform and supports the next generation of biologic therapies. About Axio BioPharma Axio BioPharma is an AI-driven biomanufacturing company revolutionizing how monoclonal antibodies are developed and produced. Headquartered in Madison, WI, Axio combines high-throughput production with proprietary machine learning to predict optimal scalable manufacturing processes in hours - not years. By accelerating development timelines and reducing costs, Axio enables biopharma innovators to bring life-saving therapies to market faster and more efficiently. With deep expertise in antibody manufacturing, protein purification, and bioinformatics, Axio supports a wide range of partners across research, diagnostics, and therapeutics with scalable, U.S.-based production and data-enhanced process design. Media Contact: Madelyn De Los Santos [email protected] Putnam Insights LLC SOURCE Axio BioPharma Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

New Delhi: India's Jubilant Pharmova reported a 51per cent jump in third-quarter profit on Friday, driven by a strong demand for its drugs with radioactive ingredients, used to treat cancer and other diseases. Consolidated net profit rose to 1.01 billion rupees ($11.7 million) in the quarter ended Dec. 31, from 668 million rupees a year ago. Revenue rose 9per cent to 18.14 billion rupees, lifted by the radiopharma segment's nearly 12per cent growth this quarter. The segment accounted for nearly 46per cent of the total revenue. The drugmaker, which manufactures and supplies radiopharmaceuticals used to diagnose and treat cancer and other diseases such as hyperthyroidism and lung diseases, has a network of 52 radio-pharmacies in the United States. Revenue from its contract manufacturing segment, the firm's second-biggest segment that makes sterile injectables, rose slightly, as did the generics business. Jubilant Pharmova's shares jumped as much as 4.5per cent after the results, but pared gains to last trade 1.5per cent higher. ($1 = 86.5940 Indian rupees) (Reporting by Nandan Mandayam in Bengaluru; Editing by Eileen Soreng)